First point-of-care PSA test for prostate cancer detection

Alexa R. Meyer, Michael Gorin

Research output: Contribution to journalArticle

Abstract

The FDA’s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement Amendments waiver is needed before this test can be fully integrated into clinical care.

Original languageEnglish (US)
JournalNature Reviews Urology
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'First point-of-care PSA test for prostate cancer detection'. Together they form a unique fingerprint.

  • Cite this